222 related articles for article (PubMed ID: 16226519)
1. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.
Brown GC; Brown MM; Campanella J; Beauchamp GR
Am J Ophthalmol; 2005 Oct; 140(4):679-87. PubMed ID: 16226519
[TBL] [Abstract][Full Text] [Related]
2. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
Brown GC; Brown MM; Brown HC; Kindermann S; Sharma S
Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Sharma S; Brown GC; Brown MM; Hollands H; Shah GK
Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079
[TBL] [Abstract][Full Text] [Related]
4. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.
Bansback N; Davis S; Brazier J
Eye (Lond); 2007 Dec; 21(12):1455-63. PubMed ID: 17086167
[TBL] [Abstract][Full Text] [Related]
5. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
Gower EW; Cassard SD; Bass EB; Schein OD; Bressler NM
Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
[TBL] [Abstract][Full Text] [Related]
7. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.
Hopley C; Salkeld G; Mitchell P
Br J Ophthalmol; 2004 Aug; 88(8):982-7. PubMed ID: 15258009
[TBL] [Abstract][Full Text] [Related]
8. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.
Grieve R; Guerriero C; Walker J; Tomlin K; Langham J; Harding S; Chakravathy U; Carpenter J; Reeves BC;
Ophthalmology; 2009 Dec; 116(12):2471-77.e1-2. PubMed ID: 19948278
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
Earnshaw SR; Moride Y; Rochon S
Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
[TBL] [Abstract][Full Text] [Related]
11. The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.
Brown GC; Brown MM; Brown HC; Kindermann S; Sharma S
Trans Am Ophthalmol Soc; 2007; 105():160-9; discussion 169-71. PubMed ID: 18427606
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of photodynamic therapy with verteporfin.
Lees MJ; Aldridge GJ; Davey PJ; Gorgievski M
Ophthalmology; 2003 Apr; 110(4):626-7; author reply 627-8. PubMed ID: 12689865
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of photodynamic therapy with verteporfin.
Lees MJ; Aldridge GJ; Davey PJ; Gorgievski M
Ophthalmology; 2003 Jun; 110(6):1263-4; author reply 1264-5. PubMed ID: 12799261
[No Abstract] [Full Text] [Related]
15. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value.
Sharma S; Bakal J; Sharma SM; Covert D; Shah GK
Can J Ophthalmol; 2005 Jun; 40(3):369-77. PubMed ID: 15947806
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case.
Smith DH; Fenn P; Drummond M
Br J Ophthalmol; 2004 Sep; 88(9):1107-12. PubMed ID: 15317697
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
Bressler NM;
Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
[TBL] [Abstract][Full Text] [Related]
18. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
Fletcher EC; Lade RJ; Adewoyin T; Chong NV
Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in age-related macular degeneration in routine clinical practice in Switzerland].
Donati G
J Fr Ophtalmol; 2007 Oct; 30(8):837-41. PubMed ID: 17978682
[TBL] [Abstract][Full Text] [Related]
20. Laser treatments with verteporfin therapy and its potential impact on retinal practices.
Margherio RR; Margherio AR; DeSantis ME
Retina; 2000; 20(4):325-30. PubMed ID: 10950407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
